HC Wainwright & Co. Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy rating and set a price target of $4.
July 30, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Adaptimmune Therapeutics with a Buy rating and set a price target of $4.
The initiation of coverage with a Buy rating and a specific price target of $4 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100